Evidence map›Paper›PMID 31424419›Full record

Observational studyJournal of Parkinson's disease2019

Treatment Patterns in Patients with Incident Parkinson's Disease in the United States.

Richard Houghton, Frank Boess, Lynne Verselis, Yingjie Ding, Rita Freitas, Niculae Constantinovici, Rose Ong

Abstract readObservational Study
In one paragraph

Observational study in Journal of Parkinson's disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Dopaminergic treatment strategies for people with Parkinson's disease in Europe: a retrospective analysis of PRISM trial data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Richard HoughtonProduct Development Personalized Health Care, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Frank BoessRoche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Lynne VerselisRoche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd., New York NY, USA.
Yingjie DingGenesis Research, Hoboken NJ, USA.
Rita FreitasProduct Development Personalized Health Care, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Niculae ConstantinoviciProduct Development Personalized Health Care, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Rose OngProduct Development Personalized Health Care, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment patterns in Parkinson's disease (PD) have not been extensively studied for nearly two decades. Insurance claims are appropriate for such analysis.

objectiveTo understand the standard of care use of symptomatic treatments in new cases of PD and factors associated with treatment choice.

methodsRetrospective cohort study using claims data from the United States between 2008 and 2016. We used Kaplan-Meier methodology to estimate time to treatment start and switch or add-on therapy and Cox proportional hazards models to identify predictors.

resultsWe identified 68,532 patients eligible for treatment pattern analyses. Median time from diagnosis until first treatment was 37 days (95% confidence interval: 36-38). Two distinct patterns of treatment initiation were identified: fast initiators and patients with delayed treatment start (or no recorded treatment). Levodopa therapies were the most commonly prescribed treatment class (52.6%). Increased age was associated with shorter time to start of treatment with levodopa. Younger age was associated with shorter time to initiation of dopamine agonists and other symptomatic treatments. Patients that initiated treatment with levodopa/combinations had the fewest switches/add-ons [30.4%; median time 7.29 (6.71, 8.13) years]. Older patients had fewer switch/add-on therapies, but only in the group that started with levodopa/combination therapy.

conclusionsTime from diagnosis to treatment start was relatively short, suggesting that PD diagnosis, as reflected in the database, is closely linked to start of symptomatic treatment. Levodopa treatment remains the most common treatment, especially for older patients. Delayed treatment start was associated with increased age and comorbidity.

Indexed as

AgedAntiparkinson AgentsDrug Therapy, CombinationFemaleHumansKaplan-Meier EstimateLevodopaMaleMiddle AgedParkinson DiseaseProportional Hazards ModelsRetrospective StudiesUnited StatesAntiparkinson AgentsLevodopaCharlson comorbiditiesclaims dataParkinson’s diseasetreatment patternsUnited States

Identifiers

PMID31424419
PMCPMC6839607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.